Nuvation Bio Inc. (NUVB) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlighted strong financial metrics with $549 million in cash and a significant increase in new patient starts for IBTROZI. However, management's reluctance to provide specific sales guidance and lack of details on the IDH1 program raise concerns. The advanced European partnership talks and expected $25 million milestone are positive, but the absence of clear guidance tempers optimism. The Q&A revealed a cautious analyst sentiment due to these uncertainties, leading to a neutral outlook for the stock price.
Key Financial Performance
Total Revenue $13.1 million in total revenue for the first quarter of 2025, which includes $7.7 million in net product revenue from IBTROZI. Growth is driven by treating new patients with IBTROZI, as channel stocking no longer makes up a material amount of product revenue.
R&D Expenses $28.8 million for the quarter, driven by continued investment in IBTROZI and the clinical stage pipeline.
SG&A Expenses $37.4 million for the quarter, primarily driven by support for commercialization, including personnel-related expenses tied to commercial operations, medical education, payer engagement, patient support programs, and marketing.
Cash Balance $549 million in cash, cash equivalents, and marketable securities at the end of the quarter. An additional $50 million is available under a term loan agreement with Sagard Healthcare Partners.
IBTROZI New Patient Starts 204 new patients started treatment with IBTROZI in the third quarter, equivalent to over 15 new patient starts per week. This is 5x greater than the next most recent therapeutic benchmark in this indication.
Gross-to-Net Adjustment Gross-to-net level increased to approximately 20%, expected to slightly increase over time and then stabilize.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
IBTROZI launch: IBTROZI received FDA approval on June 11, 2025, marking the company's transition to a commercial stage. In Q3 2025, 204 new patients started treatment, averaging over 15 new patient starts per week. The drug is being positioned as the new standard of care for ROS1-positive non-small cell lung cancer due to its efficacy, durability, and tolerability.
Safusidenib development: Safusidenib is being developed for IDH1-mutant glioma, a brain cancer with limited treatment options. A global randomized study for high-grade IDH1-mutant glioma has begun, with plans to expand it into a pivotal Phase III study. Safusidenib has shown promising efficacy, including a 33% ORR in low-grade glioma and 17% ORR in high-grade glioma.
NUV-1511 update: NUV-1511, a candidate from the Drug-Drug Conjugate platform, is in Phase I dose escalation studies for solid tumors. Updates are expected soon.
Market expansion for IBTROZI: IBTROZI received regulatory approval in Japan and China, with plans for further expansion in Europe and other territories. The drug is covered by payers representing over 80% of covered lives in the U.S.
Revenue generation: In Q3 2025, the company generated $13.1 million in total revenue, including $7.7 million from IBTROZI. The company expects a $25 million milestone payment from its Japanese partner and additional royalties from global partnerships.
Cost management: The company decided not to pursue a costly head-to-head study for safusidenib, reallocating resources to other priorities. This decision is expected to lower operating expenses and extend the cash runway.
Focus on high-grade glioma: The company is prioritizing the development of safusidenib for high-grade IDH1-mutant glioma, a high unmet need area, instead of pursuing a head-to-head study against vorasidenib.
Adjuvant study for IBTROZI: The TRUST-IV study was initiated to evaluate IBTROZI as an adjuvant therapy for early-stage ROS1-positive non-small cell lung cancer, aiming to expand its use and solidify its leadership in this indication.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory and Approval Challenges: The company faces challenges in obtaining regulatory approvals for its products in various regions, such as the need for a head-to-head study against vorasidenib for safusidenib approval in the U.S., which was deemed financially unfeasible.
Clinical Trial Complexity and Duration: The high-grade IDH1-mutant glioma study for safusidenib is expected to take years to complete, with no interim updates due to the blinded protocol, potentially delaying market entry and revenue generation.
Market Access and Reimbursement: While IBTROZI has achieved 80% coverage in the U.S., payer engagement and reimbursement approvals in other regions, such as Europe, remain uncertain and could impact revenue growth.
Competitive Pressures: The company faces competition from existing therapies like vorasidenib and other ROS1 TKIs, which may limit market share and adoption of its products.
Supply Chain and Manufacturing Risks: The company relies on partnerships for commercialization in regions like Japan and China, which could pose risks related to supply chain disruptions or partner performance.
Financial Sustainability: The decision to not pursue a costly head-to-head study against vorasidenib was financially prudent, but it highlights the company's need to carefully manage its cash reserves to fund operations through profitability.
Strategic Execution Risks: The company’s ability to execute on its pipeline development, including the TRUST-IV study and safusidenib trials, is critical but fraught with risks related to trial enrollment, regulatory hurdles, and resource allocation.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
IBTROZI's future performance: IBTROZI is expected to become the new standard of care for ROS1-positive non-small cell lung cancer due to its robust efficacy, durability, and tolerability. The company plans to submit a supplemental NDA for a label update based on new data showing a median duration of response (DOR) of 50 months. The company is also preparing to present additional data at a medical conference in 2026.
Adjuvant therapy study for IBTROZI: The company has initiated the TRUST-IV Phase III study to evaluate IBTROZI as an adjuvant therapy for resected ROS1-positive early-stage non-small cell lung cancer. This study aims to address the unmet need of preventing disease recurrence after surgery and could further expand IBTROZI's market.
Market expansion for IBTROZI: The company is exploring RNA-based testing, which could increase the annual addressable population for IBTROZI in the U.S. from 3,000 to approximately 4,000 patients. This expansion could lead to a theoretical maximum of over 16,000 patients treated by the fifth year post-approval.
Global commercialization of IBTROZI: IBTROZI has received regulatory approval in Japan and China, with plans to expand to Europe and other ex-U.S. territories. The company expects to receive a $25 million milestone payment from its Japanese partner and start receiving royalty payments.
Safusidenib development: The company is focusing on a pivotal Phase III study for safusidenib in high-grade IDH1-mutant glioma, with an estimated completion in 2029. The study aims to address a significant unmet need and could support regulatory approvals. The company has decided not to pursue a head-to-head study against vorasidenib due to financial considerations.
Financial outlook: The company expects its cash balance of $549 million to fund operations through profitability. Additional revenue is anticipated from milestone payments and royalties from global partners. The company is also exploring external opportunities to expand its pipeline.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you provide guidance on sales for IBTROZI this year and discuss trends in usage between treatment-naive and second-line settings?
A:Management did not provide specific guidance on sales but expressed comfort with the current consensus. They highlighted $7.7 million in net sales for Q3 in the U.S. and noted an increasing proportion of first-line patients over time due to shorter PFS in second-line patients.
Q:How many patients were on the expanded access program (EAP), and what is the future direction of EAP and the fast access program?
A:Only 6 patients from the EAP were converted to commercial IBTROZI. Management expects these programs to support adoption as physicians gain more experience with the drug. They also mentioned that if patients stay on IBTROZI for a full year, it could generate approximately $55 million in sales.
Q:Can you provide details on the gross-to-net and payer mix, and the timeline for submitting the supplemental NDA for IBTROZI?
A:The gross-to-net is roughly 20%, with payer mix including 40% from Medicare, less than 10% from Medicaid, and about 20% from 340B. Management anticipates submitting the supplemental NDA by the end of the week.
Q:Can you share details on the IDH1 program, including powering assumptions and crossover provisions for the high-grade glioma study?
A:Management did not provide details on powering assumptions but mentioned a trial size of 150 per arm for registration. They did not disclose the number of events required for data accumulation.
Q:Is the current rate of 15 new patients per week sustainable, and can you provide insights on TRX numbers or prescription refills?
A:Management expects continuous growth without a bolus of patients. They noted challenges with IQVIA data accuracy but anticipate improvements by February or March. Growth is expected from market penetration, increased testing awareness, and revenue stacking due to IBTROZI's long duration of response.
Q:What is the status of the European partnership and the $25 million Nippon milestone?
A:The European partnership is in advanced discussions, with details expected in Q4. The $25 million Nippon milestone is expected in Q4 as it is tied to the reimbursement list in Japan.
Q:How do you view the first-line versus second-line use of IBTROZI, and how might competitors impact the market?
A:Management expects to capture the majority of treatment-naive patients (3,000 annually in the U.S.) and TKI-experienced patients. They anticipate growth as the standard of care shifts to RNA testing, increasing the pool to 4,000 new patients annually. They expressed confidence in IBTROZI's metrics compared to competitors.
Q:What are your thoughts on consensus for next year and collaboration license revenues?
A:Management is comfortable with the consensus of $115 million for 2026. Collaboration revenues from deferred revenue with Nippon Kayaku will decrease, but royalties from China, Nippon Kayaku, and a potential European partnership will increase.
Q:How are you preparing for competitors and is your sales force fully built out?
A:Management expressed confidence in IBTROZI's metrics and noted no new competitors in the first-line setting next year. The sales force is fully built out with no plans for expansion.
Q:What is the added benefit of the new label with the long DOR, and what is IBTROZI's current market share?
A:The new label will solidify IBTROZI's position as the standard of care and provide updated information to healthcare providers. Management did not provide specific market share data but noted that IBTROZI's launch is outperforming others in the space.
Q:What insights can we expect from the NUV-1511 data by year-end?
A:Management will present the data accumulated to date from the clinical trial, but no specific insights or impact were detailed.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the number of events required for the IDH1 program's data accumulation and did not disclose IBTROZI's exact market share due to limitations in IQVIA data.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
ALK cell
IBTROZI disease
IBTROZI efficacy
IBTROZI patient
IBTROZI response
IBTROZI safety
II study
INDIGO study
IQVIA
LORBRENA ALK
Nippon Kayaku
Nuvation Bio
PFS endpoint
ROS TrkB
ROS cell
TKI patient
TRUST II
TRUST IV
Today
WCLC
approval IBTROZI
grade IDH
grade patient
label
launch IBTROZI
medicine
momentum
patient IBTROZI
patient start
prescription
profile IBTROZI
risk grade
start week
study IBTROZI
vorasidenib
NUVB Transcript
Nuvation Bio Inc. (NUVB) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
Neutral5-25
Nuvation Bio Inc. (NUVB) Presents at H.C. Wainwright 4th Annual BioConnect Investor Conference Transcript
Neutral5-22
Nuvation Bio Inc. (NUVB) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Neutral5-13
Nuvation Bio Inc. (NUVB) Q1 2026 Earnings Call Transcript
Unknown5-4
The earnings call summary indicates mixed signals. On the positive side, there is a 12% YoY revenue increase and a reduced net loss, suggesting improved financial performance. However, concerns arise from increased G&A expenses and the lack of discussion on shareholder returns. The acknowledgment of risks and uncertainties in forward-looking statements adds caution. With no new partnerships or guidance changes, and considering the cash runway's stability, the overall sentiment is neutral, expecting minimal stock movement.
NUVB Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
